Tài liệu tham khảo
1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the
evaluation and management of chronic kidney disease. Kidney Inter. 2013;3(Supp):1-150.
2. Reese PP, Cappola AR, Shults J, et al. Physical performance and frailty in chronic kidney disease. Am J Nephrol. 2013;
38(4):307-315.
3. Vincent JL. Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol. 2009;23(2):183-191.
4. Bhutto A, Morley JE. The clinical significance of gastrointestinal changes with aging. Curr Opin Clin Nutr Metab Care.
2008;11(5): 651-660.
5. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ 2008;336 (7654):1185-1189.
6. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical
applications. Br J Clin Pharmacol. 2004;57(1):6-14.
7. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601-610.
8. Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol.
2014;88(7):1351-1389.
9. Keller F, Maiga M, Neumayer HH, Lode H, Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in
renal disease. Eur J Drug Metab Pharmacokinet. 1984;9(3):275-282.
10. Tajiri K, Shimizu Y. Liver physiology and liver diseases in the elderly. World J Gastroenterol. 2013;19(46):8459-8467.
11. Turnheim K. Drug therapy in the elderly. Exp Gerontol. 2004; 39(11-12):1731-1738.
12. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet.
2009;48(11): 689-723.
13. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol
Diagn Ther. 2013;17(3):165-184.
14. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab
Toxicol. 2008;4(8):1065-1074.
15. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc.
1985; 33(4):278-285.
16. Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc.
2009;120:419-428.
17. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a
clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137.
18. Glassock RJ, Winearls CG. eGFR: Readjusting its rating. Clin J Am Soc Nephrol. 2009;4(5):867-869.
19. Farag A, Garg AX, Li L, Jain AK. Dosing errors in prescribed antibiotics for older persons with CKD: a retrospective time
series analysis. Am J Kidney Dis. 2014;63(3):422-428.
20. Corsonello A, Pedone C, Lattanzio F, et al. Agreement between equations estimating glomerular filtration rate in elderly
nursing home residents and in hospitalised patients: Implications for drug dosing. Age Ageing. 2011;40 (5):583-589.
21. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse
drug reactions. Curr Med Chem. 2010;17(6):571-584.
22. Gianni M, Bosch J, Pogue J, et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J.
2007;28 :1382-1388.
23. Chaudhry KN, Chavez P, Gasowski J, Grodzicki T, Messerli FH.Hypertension in the elderly: some practical considerations.
Cleve Clin J Med. 2012;79(10):694-704.
24. Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis. 2002; 44(4):251-266.
25. Mansfield AS, Qian Q. 71-year-old man with chronic kidney failure and sudden change of mental status. Mayo Clin Proc.
2009;84(11):e5-e8.
26. Beijer HJM, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies.
Pharm World Sci. 2002;24(2):46-54.
27. Cantú TG, Ellerbeck EF, Yun SW, Castine SD, Kornhauser DM. Drug prescribing for patients with changing renal function.
Am J Hosp Pharm. 1992;49(12):2944-2948.
28. Sharif-Askari FS, Syed Sulaiman SA, Saheb Sharif-Askari N, Al Sayed Hussain A. Development of an adverse drug reaction
risk assessment score among hospitalized patients with chronic kidney disease. PLoS One. 2014;9 (4):e95991.
29. Son H, Lee D, Lim LA, Jang SB, Roh H, Park K. Development of a pharmacokinetic interaction model for co-administration
of simvastatin and amlodipine. Drug Metab Pharmacokinet. 2014; 29(2):120-128.
30. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding
adjustment of dose for renal function. BMJ. 2005;331(7511):263.
31. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin
Pharmacol. 2009;65(8):757-773.
32. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria
for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-631.
33. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and
START (Screening Tool to Alert doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):7283.
34. Patterson SM, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older
people.Cochrane Database Syst Rev. 2014;10:CD008165.
35. Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL. Efficacy and safety of combined vs. single
renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens. 2013;26(3):424-441.
36. Rossignol P, Dobre D, McMurray JJV, et al. Incidence, determinants, and prognostic significance of hyperkalemia and
worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo
in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in
Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7(1):51-58.
37. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate
(Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264.e9-e24.
38. Kamel KS, Schreiber M. Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia?
Nephrol Dial Transplant. 2012;27(12):4294-4297.
39. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days
among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223-2233.
40. Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen
Intern Med. 1998;13:735-739.
41. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time
profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507-514.
42. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193-209.
43. Hung CC, Kuo MC, Chang JM, Chen HC. Fluoroquinoloneinduced acute interstitial nephritis in immunocompromised
patients: two case reports. Nephrol Dial Transplant. 2006;21(1):237-238.
44. Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage
levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother. 2013;
47(12):1618-1626.
45. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH,Mamdani MM. Trimethoprim-sulfamethoxazole-induced
hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med.
2010;170(12):1045-1049.
46. Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the
elderly: a population-based study. Br J Clin Pharmacol. 2011;71(4):544-549.
47. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following co-prescription of macrolide
antibiotics and calcium-channel blockers. CMAJ. 2011;183(3):303-307.
48. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Man ageing the underestimated risk of statin-associated myopathy. Int J
Cardiol. 2012;159:169-176.
49. Chan AL, Wang MT, Su CY, Tsai FH. Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart
failure patients: a population-based study. Eur J Clin Pharmacol.2009;65(12):1237-1243.
50. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral
anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153(14):16651670.
51. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney
disease and is associated with an increased mortality rate. Kidney Int. 2011;80(2):181-189.
52. Taksande SR, Worcester EM. Calcium supplementation in chronic kidney disease. Expert Opin Drug Saf. 2014;13(9):11751185.
53. Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adultsda systematic review. J Geriatr
Psychiatry Neurol. 2012;25(1):51-61.
54. Bocchetta A, Ardau R, Carta P, et al. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross
sectional study. BMC Med. 2013;11:33.
55. Zaidan M, Stucker F, Stengel B, et al. Increased risk of solid renal tumors in lithium-treated patients. Kidney Int.
2014;86(1):184-190.
56. Hanchard B, Boulouffe C, Vanpee D. Sulfonylurea-induced hypoglycaemia: use of octreotide. Acta Clin Belg.
2009;64(1):56-58.
57. Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care. 1992;15(1):75-80.
58. Stades AME, Heikens JT, Erkelens DW, Holleman F,Hoekstra JB. Metformin and lactic acidosis: cause or coincidence?A
review of case reports. J Intern Med. 2004;255(2):179-187.
59. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes.
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a
consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes
Care. 2009;32(1):193-203.
60. Elmore LK, Baggett S, Kyle JA, Skelley JW. A review of the efficacy and safety of canagliflozin in elderly patients with type
2 diabetes. Consult Pharm. 2014;29(5):335-346.
61. Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample
of older adults. JAMA Intern Med. 2014;174(4):588-595.
62. Andersson C, Shilane D, Go AS, et al. b-Blocker therapy and cardiac events among patients with newly diagnosed coronary
heart disease. J Am Coll Cardiol. 2014;64(3):247-252.
63. Kuyper LM, Khan NA. Atenolol vs nonatenolol b-blockers for the treatment of hypertension: a meta-analysis. Can J
Cardiol.2014;30(5, suppl):S47-S53.
64. Stason WB, Schmid CH, Niedzwiecki D, et al. Safety of nifedipine in patients with hypertension: a meta-analysis [published
correction appears in Hypertension. 1999;34(3):531]. Hypertension. 1997;30(1, pt 1):7-14.
65. Jung SY, Choi NK, Kim JY, et al. Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurology.
2011;77(13):1229-1234.
66. Miyagawa K, Dohi Y, Nakazawa A, et al. Renoprotective effect of calcium channel blockers in combination with an
angiotensin receptor blocker in elderly patients with hypertension: a randomized crossover trial between benidipine and
amlodipine. Clin Exp Hypertens. 2010;32(1):1-7.
67. Fliser D, Schröter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in
patients with advanced renal failure. Kidney Int. 1994;46(2):482-488.
68. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51(25):2375-2384.
69. Takenaka T, Takane H, Kikuta T, Watanabe Y, Suzuki H. Statin improves flow-mediated vasodilation in chronic kidney
diseases.Int J Hypertens. 2013;2013:876-865.
70. Baigent C, Landray MJ, Reith C, et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus
ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled
trial.Lancet. 2011;377(9784):2181-2192.
71. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease
not requiring dialysis. Cochrane Database Syst Rev. 2014;5:CD007784.
72. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin
trials.Lancet 2010;375(9716):735-742.
73. Bilge U, Sahin G, Unluoglu I, Ipek M, Durdu M, Keskin A. Inappropriate use of nonsteroidal anti-inflammatory drugs and
other drugs in chronic kidney disease patients without renal replacement therapy. Ren Fail. 2013;35(6):906-910.
74. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal
antiinflammatory drugs with acute renal failure: a population-based,nested case-control analysis. Am J Epidemiol. 2006;164:881889.
75. Townsend RR, Cohen DL. Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the
risk of acute kidney injury. Evid Based Med. 2013;18(6):232-233.
76. Kikuchi H, Aoyagi M, Nagahama K, et al. Nephrotic-range proteinuria
and interstitial nephritis associated with the use of a topical loxoprofen patch. Intern Med. 2014;53(11):1131-1135.
77. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological
management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346.
78. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term
risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5(12):2954-2960.
79. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases.
International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992;326(25):1654-1660.
80. Kuypers DRJ. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging
2009;26(9):715-737.
81. Nankivell BJ, Murali KM. Images in clinical medicine: renal failure from vitamin C after transplantation. N Engl JMed.
2008;358(4):e4.
82. Ingelsson E, Lind L. Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care
2009;32(4):733-735.
83. Henze A, Frey SK, Raila J, et al. Evidence that kidney function but not type 2 diabetes determines retinol-binding protein 4
serum levels. Diabetes. 2008;57(12):3323-3326.
84. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int.
2009;75(1):88-95.
85. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international
studies.Am J Med. 2011;124(6):519-526.
86. McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol.
2010;26(6):624-631.
87. Corsonello A, Maggio M, Fusco S, et al. Proton pump inhibitors and functional decline in older adults discharged from acute
care hospitals. J Am Geriatr Soc. 2014;62(6):1110-1115.
88. Luk CP, Parsons R, Lee YP, Hughes JD. Proton pump inhibitorassociated hypomagnesemia: what do FDA data tell us? Ann
Pharmacother. 2013;47(6):773-780.
89. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC
Nephrol. 2013;14:150.
90. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144-153.
91. Kirby D, Ames D. Hyponatraemia and selective serotonin reuptake inhibitors in elderly patients. Int J Geriatr Psychiatry.
2001;16(5):484-493.
92. Zalai D, Szeifert L, Novak M. Psychological distress and depression in patients with chronic kidney disease. Semin Dial.
2012; 25(4):428-438.
93. Harugeri A, Joseph J, Parthasarathi G, Ramesh M, Guido S. Potentially inappropriate medication use in elderly patients: a
study of prevalence and predictors in two teaching hospitals. J Postgrad Med. 2010;56(3):186-191.
94. Schaeffner ES, Ebert N, Delanaye P, et al. Two novel equations to estimate kidney function in persons aged 70 years or older.
Ann Intern Med. 2012;157(7):471-481.
95. Doak MW, Nixon AC, Lupton DJ, Waring WS. Self-poisoning in older adults: patterns of drug ingestion and clinical
outcomes.Age Ageing. 2009;38(4):407-411.
96. Barry PJ, Gallagher P, Ryan C, O’mahony D. START (screening tool to alert doctors to the right treatment) an evidence
based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36(6):632-638.
97. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication
compliance.Clin Ther. 2001;23(8):1296-1310.
98. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter
medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.